Senior Interventional Cardiologist, Apollo Multispeciality Hospitals, Kolkata

The Review of Current Practices (RCP) on venous thromboembolism (VTE) kicks off with a focused and clinically rich Day 1, chaired by Lt Gen (Dr.) Velu Nair (Retd.). Designed for busy clinicians, the evening features 3 expert-led sessions that lay the foundation for evidence-based VTE management.

The agenda begins with an overview of contemporary approaches, followed by a discussion of thromboprophylaxis and risk stratification, emphasizing translation of evidence into real-world clinical decision-making. This is complemented by a session on catheter-related thrombosis, bringing in interventional and surgical perspectives.

The day culminates in an in-depth panel discussion, focusing on personalizing VTE management in complex “grey zone” populations, including obesity, bleeding risk, renal dysfunction, and young adults.

With interactive elements such as live polls, audience Q&A, and case-based insights, Day 1 sets the stage for a practical, nuanced understanding of VTE management. Participants will also engage through pre–post assessments, with certificates awarded upon completion.

RCP VTE 2026 - Day 1

This session includes a comprehensive evidence-based strategies for VTE thromboprophylaxis and risk stratification, translating current guidelines into real-world clinical decision-making. The session examines validated risk scoring tools, patient selection criteria, and the challenges of implementing prophylaxis protocols across diverse clinical settings.

Interventional vs Medical Management of VTE: Are We Choosing the Right Patients?

Day 2 of the Review of Current Practices (RCP) on venous thromboembolism (VTE) builds on foundational concepts with a sharper focus on high-risk scenarios and evolving treatment paradigms. Chaired by Lt Gen (Dr.) Velu Nair (Retd.), the day features 4 expert-led sessions designed to refine clinical decision-making.

The evening begins with a recap of key Day 1 insights, followed by a keynote by Dr. Velu Nair on cancer-associated thrombosis, addressing treatment complexities in high-risk patients. Then presents emerging evidence in anticoagulation, with insights from the COBRRA trial and its clinical implications.

Subsequent sessions include rationalizing the use of DOACs, LMWH, and oral anticoagulants, and a discussion on selecting between interventional and medical management strategies in VTE.

The program concludes with closing remarks and key takeaways, reinforcing practical application. As with Day 1, the format remains highly interactive with live polls, audience engagement, and knowledge assessments, ensuring meaningful learning outcomes for participants.

Dr. Suvro Banerjee

3

5

-

5

Upcoming Sessions